Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1972 1
1973 1
1974 1
1975 2
1977 2
1979 2
1984 5
1985 2
1986 6
1987 6
1988 8
1989 9
1990 1
1991 6
1992 8
1993 5
1994 5
1995 4
1996 6
1997 15
1998 6
1999 9
2000 5
2001 10
2002 6
2003 11
2004 11
2005 12
2006 14
2007 10
2008 22
2009 22
2010 25
2011 36
2012 26
2013 21
2014 14
2015 17
2016 17
2017 21
2018 18
2019 17
2020 19
2021 10
2022 19
2023 15
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

464 results

Results by year

Filters applied: . Clear all
Page 1
Sphingolipids as therapeutics.
Kester M, Kolesnick R. Kester M, et al. Pharmacol Res. 2003 May;47(5):365-71. doi: 10.1016/s1043-6618(03)00048-3. Pharmacol Res. 2003. PMID: 12676510 Review.
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain.
Meeuwsen MH, Wouters AK, Wachsmann TLA, Hagedoorn RS, Kester MGD, Remst DFG, van der Steen DM, de Ru AH, van Hees EP, Kremer M, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. Meeuwsen MH, et al. Among authors: kester mgd. J Hematol Oncol. 2023 Feb 27;16(1):16. doi: 10.1186/s13045-023-01408-6. J Hematol Oncol. 2023. PMID: 36850001 Free PMC article.
Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes.
Paudel BB, Tan SF, Fox TE, Ung J, Shaw J, Dunton W, Lee I, Sharma A, Viny AD, Barth BM, Tallman MS, Cabot M, Garrett-Bakelman FE, Levine RL, Kester M, Claxton D, Feith DJ, Janes KA, Loughran TP Jr. Paudel BB, et al. Among authors: kester m. bioRxiv [Preprint]. 2023 Apr 17:2023.04.13.536805. doi: 10.1101/2023.04.13.536805. bioRxiv. 2023. PMID: 37131653 Free PMC article. Updated. Preprint.
Novel strategies for managing pancreatic cancer.
Loc WS, Smith JP, Matters G, Kester M, Adair JH. Loc WS, et al. Among authors: kester m. World J Gastroenterol. 2014 Oct 28;20(40):14717-25. doi: 10.3748/wjg.v20.i40.14717. World J Gastroenterol. 2014. PMID: 25356034 Free PMC article. Review.
The use of nanoparticulates to treat breast cancer.
Tang X, Loc WS, Dong C, Matters GL, Butler PJ, Kester M, Meyers C, Jiang Y, Adair JH. Tang X, et al. Among authors: kester m. Nanomedicine (Lond). 2017 Oct;12(19):2367-2388. doi: 10.2217/nnm-2017-0202. Epub 2017 Sep 4. Nanomedicine (Lond). 2017. PMID: 28868970 Free PMC article. Review.
Formation and role of exosomes in cancer.
Brinton LT, Sloane HS, Kester M, Kelly KA. Brinton LT, et al. Among authors: kester m. Cell Mol Life Sci. 2015 Feb;72(4):659-71. doi: 10.1007/s00018-014-1764-3. Epub 2014 Oct 22. Cell Mol Life Sci. 2015. PMID: 25336151 Free PMC article. Review.
Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.
Ung J, Tan SF, Fox TE, Shaw JJP, Vass LR, Costa-Pinheiro P, Garrett-Bakelman FE, Keng MK, Sharma A, Claxton DF, Levine RL, Tallman MS, Cabot MC, Kester M, Feith DJ, Loughran TP Jr. Ung J, et al. Among authors: kester m. Blood Rev. 2022 Sep;55:100950. doi: 10.1016/j.blre.2022.100950. Epub 2022 Apr 9. Blood Rev. 2022. PMID: 35487785 Free PMC article. Review.
Nanoparticulate alternatives for drug delivery.
Adair JH, Parette MP, Altinoğlu EI, Kester M. Adair JH, et al. Among authors: kester m. ACS Nano. 2010 Sep 28;4(9):4967-70. doi: 10.1021/nn102324e. ACS Nano. 2010. PMID: 20873786 Review.
464 results